Q&A // common questions
Thymosin Alpha-1: your questions, answered straight
Direct, cited answers to the questions people actually ask about Thymosin Alpha-1 — what it is, what it does, whether it's approved, and how it stacks up against the peptides it's confused with.
Does thymosin alpha 1 reduce the mortality of severe COVID-19?
In some studies, yes; overall, it's unproven. A retrospective review of 76 severe COVID-19 patients linked Tα1 to lower mortality (11.11% vs 30.00%, P=0.044) and recovering T-cell numbers [6]. But a 2022 meta-analysis of 5,352 patients found no statistically significant overall mortality benefit, with possible value only in specific subgroups like those over 60 [12]. Encouraging in places, not confirmed at the population level.
What is thymosin alpha 1?
Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus (as part of thymosin fraction 5) by Goldstein and colleagues, who purified it and determined its complete amino-acid sequence in 1977 [1]. The acetyl cap is essential for its activity, and in the body it's cleaved from a larger precursor, prothymosin alpha [1].
What does thymosin alpha 1 do?
It tunes the immune system. Thymosin alpha-1 signals through TLR2 and TLR9 on dendritic cells, maturing them and driving T-cell responses and Th1 polarization, while also activating a regulatory (IDO) pathway that calms inflammation [5][9]. The net effect is a dual modulator: it can restore depleted immunity and damp overreactions, rather than simply boosting immune activity.
What is thymosin alpha 1 used for?
In the countries where it's approved, it's used mainly for chronic viral hepatitis and as an immune adjuvant. Research has also explored it in sepsis, COVID-19, HIV immune reconstitution, vaccine augmentation, and cancer. A 2019 reappraisal positions it as an immunostimulatory adjuvant alongside chemo- and immunotherapies in melanoma, hepatocellular carcinoma, and lung cancer [7]. It is not approved for any of these in the US.
Is thymosin alpha 1 FDA-approved?
No. Thymosin alpha-1 (generic name thymalfasin) is not FDA-approved for marketing in the United States, though it's approved in roughly 35 other countries [4]. In the US it exists only in investigational and compounding/research contexts. Its evidence is also genuinely mixed: the largest sepsis trial, the phase-3 TESTS study of 1,106 adults, found no mortality benefit (HR 0.99, P=0.93) [3].
What is TA1 peptide?
TA1 peptide is just shorthand for thymosin alpha-1 — the same 28-amino-acid, acetylated thymic immune peptide that Goldstein and colleagues isolated and sequenced from calf thymus in 1977 [1]. It's an immunomodulator that works through dendritic-cell signaling, not an anabolic, growth, or performance compound. The synthetic, sequence-identical drug form is called thymalfasin.
Who should not take thymosin alpha 1?
This isn't medical advice, but the literature flags theoretical cautions: people with established autoimmune disease (an immunostimulant is a theoretical concern, though Tα1 levels are actually lower in those conditions) [11], and solid-organ transplant recipients (whose immunosuppression it could theoretically work against) [5]. Pregnancy and lactation data are absent [4]. Anyone with a medical condition should consult a qualified clinician.
Is TB-500 the same as thymosin alpha 1?
No — they're different molecules. TB-500 is thymosin beta-4, a 43-amino-acid actin-binding peptide associated with tissue repair, and it's the one on the WADA prohibited list. Thymosin alpha-1 is a 28-amino-acid immune-signaling peptide that works through TLR2/TLR9 on dendritic cells [1][9]. Different sequence, size, mechanism, and use — they only share the word "thymosin."
How long should you take thymosin alpha 1?
Durations in studies varied by indication, and none of this is a recommendation. Sepsis trials ran 5–7 days [2][3]; COVID-19 cohorts dosed daily over the acute illness [6]; the chronic-hepatitis regimen is twice weekly long-term; and a cancer-adjuvant study used weekly injection for up to 12 months [4]. These are durations studied in trials, reported for context only.
How long does it take for thymosin alpha 1 to work?
Pharmacologically, blood levels peak within about 1–2 hours of a subcutaneous injection and return toward baseline within roughly 24 hours [4]. But its immune effects are biochemical and play out over a course of treatment, not in a single felt moment — which is why many people report not sensing anything acute. There's no reliable "onset" you'd feel the way you'd feel a stimulant.
What is the dosing protocol for thymosin alpha 1?
Studied protocols (not recommendations) center on subcutaneous injection. A four-decade review reports single doses of 0.8–6.4 mg and multiple-dose regimens of 1.6–16 mg over 5–7 days, with 1.6 mg twice weekly the familiar hepatitis pattern [4]. Sepsis trials used 1.6 mg every 12 hours for 5–7 days [2][3]. These describe what researchers administered to patients, not a personal protocol.
How does thymosin alpha 1 make you feel?
Most people report not feeling much, which makes sense for an immune modulator whose action is biochemical rather than sensory. Anecdotally, some describe a general sense of resilience or steadier energy during recovery, but these are subjective impressions prone to expectation effects, not measured outcomes. The most commonly reported physical sensation is mild irritation at the injection site [4][10].
How much thymosin alpha 1 should I take?
This site doesn't give dosing advice, and there's no human dose to recommend here. For context only, the research literature describes single subcutaneous doses of 0.8–6.4 mg and a common 1.6 mg twice-weekly hepatitis regimen — as doses studied in clinical populations [4]. What's right for any individual is a question for a qualified clinician, not a website, and Tα1 isn't approved in the US.
When is the best time to take thymosin alpha 1?
There's no established "best time" in the literature, and timing isn't something this site can recommend. Trial protocols simply specified frequency — twice weekly for hepatitis, every 12 hours for sepsis, daily for COVID-19 cohorts — rather than a time of day [2][3][4][6]. Since its effects are biochemical and cumulative across a course, no specific clock time has been shown to matter.
Is thymosin alpha 1 safe to take?
In the clinical literature it's generally well tolerated. Post-marketing surveillance across more than 600,000 treated patients found mild injection-site reactions and occasional transient flu-like symptoms as the dominant adverse events, with no documented organ toxicity at studied doses [10]. That said, US research-grade material is unregulated for purity and identity [4], and any decision about use belongs with a qualified clinician — this is editorial information, not medical advice.
Does thymosin alpha 1 help cancer?
It's been studied as an adjuvant, with some encouraging signals but no broad proof. A 2019 reappraisal frames it as an immunostimulatory adjuvant in melanoma, hepatocellular carcinoma, and lung cancer, potentially helping "turn a cold tumour hot" and easing checkpoint-inhibitor toxicity [7]. In HBV-related hepatocellular carcinoma after surgery, it was an independent predictor of better survival in one matched analysis [13]. These are specific, study-attributed findings, not a general cancer treatment.
Is thymosin alpha 1 worth it?
That depends entirely on the setting and the evidence you weigh, and it's not a call this site makes. The signal is steadiest in chronic viral hepatitis; it's genuinely null in the biggest sepsis trial (HR 0.99) [3]; and it's mixed in COVID-19 [6][12][14]. It's also not FDA-approved in the US, and research-grade quality is unregulated [4]. An honest answer reads the personal hype against that evidence, not instead of it.
Does thymosin affect aging?
Circulating thymosin alpha-1 levels decline with age, and the peptide's role in immunosenescence (the age-related weakening of immunity) is a recognized research interest, particularly in vaccine-adjuvant work aimed at older adults [11]. But "affects aging" overstates it: there's no evidence Tα1 slows aging itself. The interest is narrower — supporting an immune system that naturally weakens over time.
Has anyone tried thymosin alpha 1 for chronic illness or immune issues?
Yes — both in formal research and in research-use communities. Clinically, it's been studied in chronic viral hepatitis, HIV immune reconstitution, and immune-restoration settings [4]. Anecdotally, people with post-viral fatigue or long-term immune complaints report steadier energy and fewer infections, but these are personal impressions, clearly not clinical evidence, and not a substitute for a real medical workup of the underlying condition.
Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?
They're different molecules that only share a name. Thymosin alpha-1 is a 28-amino-acid immune-signaling peptide working through TLR2/TLR9 on dendritic cells [1][9]. Thymosin beta-4 (TB-500) is a 43-amino-acid actin-binding peptide associated with tissue repair, and it's the WADA-prohibited one. Different sequence, size, mechanism, and use. The full side-by-side is on the mechanism of action page.
What dose of thymosin alpha 1 are people running?
This site reports studied doses, not what individuals run, and gives no dosing advice. For research context, the literature describes single subcutaneous doses of 0.8–6.4 mg, multiple-dose regimens of 1.6–16 mg over 5–7 days, and a common 1.6 mg twice-weekly hepatitis pattern — all as doses administered in clinical trials [4]. Self-administering an unapproved, unregulated research-grade peptide carries quality and identity risks independent of the molecule [4].
Any side effects from thymosin alpha 1 injections?
The most common is mild injection-site reaction — redness, itching, burning, or brief stinging where the subcutaneous shot goes in [4][10]. A minority report an occasional short-lived flu-like or achy feeling, sometimes early in a course [10]. Large post-marketing surveillance documents no organ toxicity at studied doses, making local reactions the dominant adverse event [10].